# A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Source: https://onco.cc/trials/nct04008797/  
OnCo record `nct04008797` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lenvatinib and Doxorubicin in endometrial cancer, hepatocellular carcinoma and colorectal cancer, run by Eisai Inc., active and no longer recruiting.

## Summary

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor is a phase 1/2 interventional study registered as NCT04008797 by Eisai Inc., with 301 participants enrolled, started 2019-07-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: E7386, Lenvatinib, Doxorubicin and Paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04008797
- Phase: 1/2
- Setting: An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
- Sponsor: Eisai Inc.
- Enrolled: 301

## Sources

- ClinicalTrials.gov NCT04008797: https://clinicaltrials.gov/study/NCT04008797

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/)
- companies: [Eisai](https://onco.cc/companies/eisai/)

---
JSON: https://onco.cc/api/v1/entities/nct04008797.json